ACE and COVID-19: Pulmonary endothelial injury can cause a systemic angiotensin peptide profile similar to ACE inhibition, perhaps explaining why trials of de novo ARBs in COVID-19 have been neutral so far and could explain why there was an increased risk of hypotension with losartan use in our trial and a trend with ARBs in a meta-analysis [21].